<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-34 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-34</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-34</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-4.html">extraction-schema-4</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <p><strong>Paper ID:</strong> paper-3267e0013725e1dfe496c1385f4d8d5782c78f06</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/3267e0013725e1dfe496c1385f4d8d5782c78f06" target="_blank">Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Medicine</p>
                <p><strong>Paper TL;DR:</strong> In patients with locally advanced or metastatic SCC, who are not candidates for surgery or radiotherapy, anti-PD1 agents such as cemiplimab, pembrolizumab, and cosibelimab have shown significant results in terms of response rate.</p>
                <p><strong>Paper Abstract:</strong> Advanced melanoma and non-melanoma skin cancers (NMSCs) are burdened with a dismal prognosis. To improve the survival of these patients, studies on immunotherapy and target therapies in melanoma and NMSCs are rapidly increasing. BRAF and MEK inhibitors improve clinical outcomes, and anti-PD1 therapy demonstrates better results than chemotherapy or anti-CTLA4 therapy in terms of the survival of patients with advanced melanoma. In recent years, the combination therapy of nivolumab plus ipilimumab has gained ground in studies for its survival and response rate benefits in patients with advanced melanoma. In addition, neoadjuvant treatment for stages III and IV melanoma, either as monotherapy or combination therapy, has recently been discussed. Another promising strategy evaluated in recent studies is the triple combination of anti-PD-1/PD-L1 immunotherapy and anti-BRAF plus anti-MEK targeted therapy. On the contrary, in advanced and metastatic BCC, successful therapeutic strategies, such as vismodegib and sonidegib, are based on the inhibition of aberrant activation of the Hedgehog signaling pathway. In these patients, anti-PD-1 therapy with cemiplimab should be reserved as the second-line therapy in case of disease progression or poor response. In patients with locally advanced or metastatic SCC, who are not candidates for surgery or radiotherapy, anti-PD1 agents such as cemiplimab, pembrolizumab, and cosibelimab (CK-301) have shown significant results in terms of response rate. PD-1/PD-L1 inhibitors, such as avelumab, have also been used in Merkel carcinoma, achieving responses in half of the patients with advanced disease. The latest prospect emerging for MCC is the locoregional approach involving the injection of drugs that can stimulate the immune system. Two of the most promising molecules used in combination with immunotherapy are cavrotolimod (a Toll-like receptor 9 agonist) and a Toll-like receptor 7/8 agonist. Another area of study is cellular immunotherapy with natural killer cells stimulated with an IL-15 analog or CD4/CD8 cells stimulated with tumor neoantigens. Neoadjuvant treatment with cemiplimab in CSCCs and nivolumab in MCCs has shown promising results. Despite the successes of these new drugs, the new challenges ahead will be to select patients who will benefit from these treatments based on biomarkers and parameters of the tumor microenvironment.</p>
                <p><strong>Cost:</strong> 0.025</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e34.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e34.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ASCO Guideline (melanoma adjuvant)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Systemic therapy for melanoma: ASCO guideline</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ASCO clinical guideline recommending first-line systemic/adjuvant options for resected and unresectable melanoma; specifies recommended adjuvant anti-PD-1 duration for stage III disease.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Systemic therapy for melanoma: ASCO guideline</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>ASCO guideline</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab or pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>adjuvant stage III (resected stage IIIA/B/C BRAF wild-type)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>52 weeks (fixed 1 year) of nivolumab or pembrolizumab as adjuvant therapy</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>recurrence-free survival (RFS), overall survival (OS) (adjuvant endpoints)</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Guideline recommendation draws on trials showing 1-year (52-week) adjuvant anti-PD-1 improved RFS/OS compared with placebo or observation (see KEYNOTE-054 results summarized in this review: pembrolizumab RFS 59.8% vs placebo 41.4% at 3.5 years; HR 0.59).</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>Recommendation supports a fixed 52-week (1-year) adjuvant anti-PD-1 course for resected stage III disease; no alternative shorter/longer duration recommended in guideline text quoted.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer', 'publication_date_yy_mm': '2023-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e34.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e34.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KEYNOTE-054 (EORTC 1325-MG)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase III randomized trial of adjuvant pembrolizumab versus placebo in resected high-risk stage III cutaneous melanoma; used as evidence for 1-year adjuvant anti-PD-1 therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>KEYNOTE-054 (EORTC 1325-MG/KEYNOTE-054)</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>adjuvant stage III (resected high-risk)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Adjuvant pembrolizumab given per trial protocol (review and guideline context: 52 weeks / 1 year adjuvant therapy)</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>recurrence-free survival (RFS), distant metastasis-free survival (DMFS), overall survival (OS) endpoints</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Adjuvant pembrolizumab (1 year) significantly prolonged RFS compared with placebo: at 3.5 years RFS 59.8% (95% CI 55.3-64.1) vs 41.4% (37.0-45.8); hazard ratio 0.59 (95% CI 0.49-0.70) as reported in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>The trial supports benefit of a fixed ~1-year adjuvant pembrolizumab course for resected stage III melanoma; no shorter-duration strategy endorsed in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer', 'publication_date_yy_mm': '2023-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e34.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e34.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KEYNOTE-716</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Pembrolizumab versus placebo as adjuvant therapy in completely resected, high-risk, stage II melanoma (KEYNOTE-716)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase III randomized adjuvant trial in resected high-risk stage II melanoma showing reductions in recurrence or death with pembrolizumab vs placebo at interim analyses.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Pembrolizumab versus placebo as adjuvant therapy in completely resected, high-risk, stage II melanoma (KEYNOTE-716)</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>KEYNOTE-716</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>adjuvant stage II (completely resected, high-risk stage IIB/IIC)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Adjuvant pembrolizumab per trial protocol (review context indicates standard adjuvant course; review reports recurrence reductions but does not restate exact planned duration explicitly here)</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>recurrence or death (RFS-related endpoint)</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>At interim analyses, pembrolizumab reduced recurrence or death compared with placebo: first analysis 11% vs 17% (HR 0.65, 95% CI 0.46-0.92; p=0.0066); second interim 15% vs 24% (HR 0.61, 95% CI 0.45-0.82) as reported in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>Review presents pembrolizumab benefit in adjuvant high-risk stage II but does not state an optimal duration beyond the trial-specified adjuvant course.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer', 'publication_date_yy_mm': '2023-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e34.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e34.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NCT02519322 (neoadjuvant/adjuvant nivo)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NCT02519322 (phase II neoadjuvant/adjuvant nivolumab trial described in review Table 1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase II trial with two arms: neoadjuvant nivolumab up to 4 cycles with adjuvant nivolumab up to 13 cycles, or neoadjuvant ipilimumab+nivolumab with adjuvant nivolumab up to 13 cycles; reported pathologic responses.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>NCT02519322</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab (monotherapy arm and in combination arm)</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>neoadjuvant ± adjuvant for resectable high-risk melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Neoadjuvant nivolumab up to 4 cycles; adjuvant nivolumab up to 13 cycles (protocol-specified in review table)</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>pathologic complete response (pCR), presumably objective response rate (ORR)</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Reported pCR: Arm A (neoadjuvant nivolumab) pCR 25%; Arm B (neoadjuvant ipi+nivo) pCR 45% (from the review table). No direct comparison of different total adjuvant durations within the trial reported in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>pCR rates by arm reported (25% for neoadjuvant nivolumab arm; 45% for combined ipi+nivo arm).</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Review reports higher toxicity with combined therapy in other contexts but does not give duration-specific toxicity here.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>Short neoadjuvant courses followed by ~1-year adjuvant nivolumab were tested; review does not conclude an optimal total duration beyond reporting pCR differences between regimens.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer', 'publication_date_yy_mm': '2023-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e34.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e34.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NCT02434354 (pembrolizumab peri-op)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NCT02434354 (single pre-op pembrolizumab dose then adjuvant pembrolizumab q3w for 1 year; phase I reported in review Table 1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase I trial evaluating a single preoperative dose of pembrolizumab 3 weeks before surgery followed by pembrolizumab every 3 weeks for 1 year post-op; pathologic response reported.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>NCT02434354</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>neoadjuvant single-dose + adjuvant for resectable melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Single preoperative pembrolizumab dose (3 weeks prior to surgery) then pembrolizumab every 3 weeks for 1 year following surgery (per review table)</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>pathologic complete response (pCR)</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Reported pCR ~18.5% (table shows 18.50%). No comparative durations tested within the trial as reported in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>pCR reported (≈18.5%).</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>Trial evaluated a short pre-op exposure plus a 1-year adjuvant course; review does not conclude this is superior to other duration strategies.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer', 'publication_date_yy_mm': '2023-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e34.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e34.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN (perioperative ipi+nivo)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoadjuvant vs. adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized/phase Ib comparison of perioperative (neoadjuvant+adjuvant) vs adjuvant-only ipilimumab plus nivolumab; used to explore shorter preoperative courses and their impact on EFS/OS.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant vs. adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>OpACIN (NCT02437279)</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab (in combination with ipilimumab)</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>neoadjuvant/perioperative macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Adjuvant arm: ipilimumab+nivolumab for 4 cycles (adjuvant); Perioperative arm: neoadjuvant ipilimumab+nivolumab for 2 cycles before surgery and 2 cycles after surgery (per review summary)</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>event-free survival (EFS), overall survival (OS), pathologic responses</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Perioperative (neoadjuvant + adjuvant) administration produced superior outcomes vs adjuvant-only: 4-year EFS 80% (perioperative) vs 60% (adjuvant); 4-year OS 90% vs 70% respectively, as reported in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Review notes higher toxicity with combined regimens in other studies; specific duration-toxicity tradeoffs not quantified for OpACIN in the review text.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>Perioperative (short neoadjuvant exposure combined with adjuvant) ipi+nivo produced improved EFS/OS compared to adjuvant-only in this dataset; review highlights potential advantage of neoadjuvant/perioperative scheduling but does not define an optimal anti-PD-1 monotherapy duration.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer', 'publication_date_yy_mm': '2023-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e34.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e34.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN-neo / NCT02977052 (response-adapted)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN-neo (NCT02977052) neoadjuvant/ipilimumab+nivolumab regimens and response-adapted surgery/adjuvant plan</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase II neoadjuvant trial testing different ipilimumab+nivolumab dosing schedules over short neoadjuvant windows and a response-adapted surgical/adjuvant plan that omits extensive surgery or adds 52 weeks adjuvant nivolumab depending on pathologic response.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>OpACIN-neo / NCT02977052</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab (combined with ipilimumab in neoadjuvant arms)</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>neoadjuvant for resectable stage III melanoma with response-adapted surgical/adjuvant strategy</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Neoadjuvant ipilimumab+nivolumab for short courses (examples: 2 cycles or 6 weeks); protocol includes pathway: if pCR then omit completion lymphadenectomy, if pPR limited surgery, if no response proceed to lymphadenectomy + adjuvant nivolumab for 52 weeks (per review table/text).</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>pathologic complete response (pCR), major pathologic response (MPR defined <10% viable tumor), partial pathologic response (pPR)</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td>Yes — patients with pCR could avoid lymphadenectomy; patients with pPR undergo limited lymphadenectomy; non-responders receive lymphadenectomy + adjuvant nivolumab for 52 weeks.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Reported high pathologic response rates with short neoadjuvant combination: examples in review/table include MPR 61% in one cohort; OpACIN-neo arms reported pCR/MPR rates of 47%/57% depending on dosing (see table). No direct randomized comparison of total adjuvant duration (1y vs other) reported here, but non-responders were assigned a 52-week adjuvant nivolumab course.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>High pCR/MPR rates reported for short neoadjuvant combination regimens (e.g., MPR 61%; arm-level pCRs 47% and 57% in different dosing arms); review links response categories to subsequent surgical/adjuvant decisions but does not provide long-term survival by response category in this summary.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td>Review indicates that pCR patients could avoid further invasive surgery (lymphadenectomy) and thus may stop escalation of local therapy; long-term relapse rates after stopping not provided in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Short-course neoadjuvant combination regimens achieved high response rates but higher toxicity is noted for certain dosing schedules elsewhere (higher grade 3 AEs with some dosing); review does not quantify duration-specific AE rates here.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>Review presents response-adapted strategy where short neoadjuvant exposure guides surgery and only non-responders receive a standard 52-week adjuvant anti-PD-1; review suggests this adaptive approach is promising but does not claim a definitive optimal total duration.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer', 'publication_date_yy_mm': '2023-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e34.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e34.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Amaria et al. neoadjuvant (2018)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized trial comparing neoadjuvant nivolumab monotherapy vs neoadjuvant ipilimumab plus nivolumab, reporting response rates, pathologic complete responses, and toxicity differences between short-course neoadjuvant strategies.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>Amaria et al. (2018)</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab (monotherapy) and nivolumab combined with ipilimumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>neoadjuvant for resectable high-risk melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>objective response rate (ORR), pathologic complete response (pCR), treatment-related adverse events (trAEs)</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Neoadjuvant combination (short-course ipi+nivo) produced higher ORR (73%) and pCR (45%) than nivolumab monotherapy (ORR 25%, pCR 25%), but at the cost of much higher grade 3 treatment-related AEs (73% vs 8%) as reported in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>pCR and ORR stratified by arm: combination arm pCR 45%, ORR 73%; nivolumab monotherapy pCR 25%, ORR 25%.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Markedly higher grade 3 trAEs with short-course neoadjuvant combination (73%) vs nivolumab monotherapy (8%), indicating a trade-off between short-course intensified therapy and toxicity.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>Short-course neoadjuvant combination yields higher pathologic responses but substantially increased toxicity; review presents these data but does not recommend a universally optimal duration.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer', 'publication_date_yy_mm': '2023-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e34.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e34.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Adjuvant nivolumab/pembrolizumab general (registration trials referenced)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Adjuvant anti-PD-1 trials and registration data summarized in review</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Summary statement in the review that adjuvant nivolumab or pembrolizumab for 52 weeks is first-line adjuvant therapy for resected stage III melanoma, based on multiple randomized trials showing RFS/OS benefit.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>Multiple adjuvant anti-PD-1 trials (summarized)</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab or pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>adjuvant stage III (resected)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Fixed 52 weeks (1 year) adjuvant anti-PD-1 per guideline/trial summaries</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>RFS, OS, distant metastasis-free survival</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Collective trial evidence cited supports improved RFS/OS with ~1-year adjuvant anti-PD-1 versus placebo/observation; specific trial metrics appear elsewhere in the review (e.g., KEYNOTE-054 HR 0.59 for RFS).</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>Review endorses the 52-week adjuvant anti-PD-1 schedule as standard per guidelines; does not provide evidence supporting routine shorter or longer durations for adjuvant monotherapy in melanoma within the reviewed text.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer', 'publication_date_yy_mm': '2023-02'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Neoadjuvant vs. adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma <em>(Rating: 2)</em></li>
                <li>Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma <em>(Rating: 2)</em></li>
                <li>Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial <em>(Rating: 2)</em></li>
                <li>Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicenter, randomised, phase 3 trial <em>(Rating: 1)</em></li>
                <li>Pembrolizumab versus placebo as adjuvant therapy in completely resected, high-risk, stage II melanoma (KEYNOTE-716) <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>